Among 547 episodes of C difficile infection documented in cancer patients in Australia and Spain, 50% were severe, and the 90-day recurrence rate was 16%
Patients considered highly socially vulnerable were significantly more likely to be diagnosed with severe C diff infection and die from it than less vulnerable people.
Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US hospitals remains low.
A placebo-controlled randomized trial found fecal microbiota transplantation was safe but failed to reduce recurrence of Clostridioides difficile infection.
The small-molecule protein synthesis inhibitor CRS3121 met its primary endpoints, with high rates of clinical cure at day 12 and low rates of CDI recurrence.
The vaccine didn't reduce C difficile infections in at-risk adults, but it did show the potential to reduce infection severity and limit need for medical attention.
The analysis suggests administration of Rebyota is associated with significant restoration of microbiota and bile acid composition.
Researchers say the findings suggest oversight of C diff patients by infectious disease specialists may result in better outcomes and resource management.
The treatment remained protective against recurrent C difficile infection in 86% of patients over a span of 2 years despite antibiotic exposure.
A longitudinal household study found shared C difficile strains in 17 of 28 families, with the infant detected first in most instances.
